LEADERSHIP & ADVISORS

World-Class Scientific
& Business Leadership

KOP Therapeutics is led by an experienced team of oncology scientists, drug developers, and business executives — supported by a scientific advisory board with deep expertise in RNA therapeutics, radiology, and cancer biology.

1

Principal Investigator

5

Corporate Team Members

2

Advisory Board Members

700+

Peer-Reviewed Publications

PRINCIPAL INVESTIGATORS

Scientific Founders

Dr. Mathew L. Thakur, PhD, DSc

Dr. Mathew L. Thakur, PhD, DSc

Professor of Radiology, Radiation Oncology & Urology — Thomas Jefferson University

Dr. Mathew L. Thakur is a Professor of Radiology, Radiation Oncology & Urology at Thomas Jefferson University and a glob…

CORPORATE TEAM

Executive Leadership

Tibor Gajdics

Tibor Gajdics

President, CEO & Chairman

Tibor Gajdics is the founding President, CEO & Chairman of KOP Therapeutics. He leads corporate strategy, business devel…

Marco Strub

Marco Strub

Director

Marco Strub serves as a Director of KOP Therapeutics, contributing strategic oversight and board-level governance as the…

Leigh Berryman

Leigh Berryman

Executive Fractional Director of Development

Leigh Berryman brings extensive experience in pharmaceutical development and regulatory strategy to KOP Therapeutics. As…

Aziz-Ur Rehman

Aziz-Ur Rehman

Chief Financial Controller

Aziz-Ur Rehman serves as Chief Financial Controller at KOP Therapeutics, overseeing the company's financial operations,…

Sylvie Quenneville, B.Soc.Sc.

Sylvie Quenneville, B.Soc.Sc.

VP of Strategic Development & Corporate Affairs

Sylvie Quenneville serves as VP of Strategic Development & Corporate Affairs at KOP Therapeutics. She brings deep expert…

SCIENTIFIC & ADVISORY BOARD

Scientific Advisors

Dr. Jamal Daoud, PhD

Dr. Jamal Daoud, PhD

Scientific Advisory Board Member

Dr. Jamal Daoud brings deep expertise in nucleic acid therapeutics, drug delivery systems, and nanoparticle formulation.…

Dr. Emma S. Guns

Dr. Emma S. Guns

Past Scientific Advisory Board Member

Dr. Emma S. Guns is a distinguished cancer biologist with deep expertise in prostate cancer biology, androgen receptor s…

Join the KOP Therapeutics Team

We are building a world-class team to advance our knockdown oncology platform. If you are a scientist, drug developer, or business professional passionate about RNA therapeutics, we want to hear from you.

KOP Therapeutics

Advancing tumor-targeted RNA therapeutics toward IND-enabling development, partnership, and commercialization.

Preclinical Stage

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation (including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP's prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited.

© 2026 KOP Therapeutics Inc. All rights reserved.

Montreal, Quebec, Canada · 604.256.9900